P190030/S004: ActaStim-S
FDA’s recorded scope: Approval for allowance for reconditioning of the ActaStim-S Spine Fusion Stimulator.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Theragen, Inc.. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from May 13, 2026 to May 13, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LOF appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P190030, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 11220 Assett Loop, Suite 101, Manassas, VA, 20109. Recorded on P190030/S004, decision dated May 13, 2026.
FDA’s recorded scope: Approval for allowance for reconditioning of the ActaStim-S Spine Fusion Stimulator.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.